Receive our newsletter – data, insights and analysis delivered to you
November 26, 2013

European Commission funds new alliance to combat poverty related diseases

A new collaboration co-funded with €8.5m from the European Commission has been launched to accelerate the development of new vaccines, drugs and microbicides to fight against many poverty related diseases such as tuberculosis (TB), HIV, malaria, hepatitis B and hepatitis C.

By admin-demo

A new collaboration co-funded with €8.5m from the European Commission has been launched to accelerate the development of new vaccines, drugs and microbicides to fight against many poverty related diseases such as tuberculosis (TB), HIV, malaria, hepatitis B and hepatitis C.

Co-ordinated by the Medicines and Healthcare products Regulatory Agency’s (MHRA) National Institute for Biological Standards and Control (NIBSC), the collaborative infrastructure programme, ‘European Research Infrastructures for Poverty Related Diseases’ (EURIPRED), aims to strengthen the knowledge infrastructure across diseases.

Researchers and scientists from 17 research partners in ten countries will collaborate in the new EURIPRED programme.

"By minimising fragmentation and duplication of research efforts and pooling resources, EURIPRED can improve research efficiency and effectiveness."

Despite substantial efforts to reduce the burden of poverty related diseases, HIV/AIDS, TB and malaria still account for 3.4 million deaths globally every year.

Underdiagnosis and tough treatment courses are two of the reasons for the continued prevalence, according to NIBSC.

NIBSC scientific lead at the Centre for AIDS Reagents and coordinator of EURIPRED Meghna Ramaswamy said: "By creating partnerships between European scientists and international research teams from disease endemic countries, we expect to speed-up the development of new vaccines, drugs and microbicides.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

"By minimising fragmentation and duplication of research efforts and pooling resources, EURIPRED can improve research efficiency and effectiveness."

EURIPRED includes a team of European scientists, institutes and networks in the field of poverty related diseases. The aim is to speed-up the development of new vaccines, drugs and microbicides by pooling resources, reducing duplication of research efforts thereby improving research efficiency and effectiveness.

Other objectives of the project, which will be reinforced by partners in China, Russia and Kenya, will include collaboration on the selection, development, production, and validation of reference reagents, assays, and standards and training.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU